Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. (Q37792117)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

Luigi Marzio Biasucci

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Antonella Stefanelli

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Gina Biasillo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

27 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

Clinical Chemistry and Laboratory Medicine

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1685-1691

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

Atherosclerosis — An Inflammatory Disease

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Targeting C-reactive protein for the treatment of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effect of early initiation of statins on survival in patients with acute myocardial infarction (the USIC 2000 Registry).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angiopl

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Novel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

The bimodal mortality pattern of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

More than skin deep: atherosclerosis as a systemic manifestation of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Pathogenesis and therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Statins for the prevention and treatment of infections: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.277

21 January 2018

Identifiers

DOI

10.1515/CCLM.2010.277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868311%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference